Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, reported the regulatory authorization of eftilagimod alpha manufactured at commercial 2,000L scale for use in clinical trials across multiple European countries including Germany, Belgium, Denmark, and the UK. After successfully scaling up the manufacturing process to commercial scale at WuXi Biologics, the process-related changes were presented in a substantial am...